SG10201706985UA - AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHa RESPONSES - Google Patents
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHa RESPONSESInfo
- Publication number
- SG10201706985UA SG10201706985UA SG10201706985UA SG10201706985UA SG10201706985UA SG 10201706985U A SG10201706985U A SG 10201706985UA SG 10201706985U A SG10201706985U A SG 10201706985UA SG 10201706985U A SG10201706985U A SG 10201706985UA SG 10201706985U A SG10201706985U A SG 10201706985UA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- amide
- substituted heterocyclic
- heterocyclic compounds
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201706985UA true SG10201706985UA (en) | 2017-10-30 |
Family
ID=49876960
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201706897TA SG10201706897TA (en) | 2012-11-08 | 2013-11-07 | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses |
SG10201706985UA SG10201706985UA (en) | 2012-11-08 | 2013-11-07 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHa RESPONSES |
SG11201503399XA SG11201503399XA (en) | 2012-11-08 | 2013-11-07 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201706897TA SG10201706897TA (en) | 2012-11-08 | 2013-11-07 | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503399XA SG11201503399XA (en) | 2012-11-08 | 2013-11-07 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
Country Status (38)
Country | Link |
---|---|
US (6) | USRE47929E1 (en) |
EP (3) | EP4071144A1 (en) |
JP (3) | JP6407159B2 (en) |
KR (1) | KR102195194B1 (en) |
CN (1) | CN104884454B (en) |
AR (1) | AR094452A1 (en) |
AU (4) | AU2013341186B2 (en) |
BR (1) | BR112015010102B1 (en) |
CA (1) | CA2890981C (en) |
CL (1) | CL2015001231A1 (en) |
CY (2) | CY1121188T1 (en) |
DK (2) | DK3495358T3 (en) |
EA (1) | EA028814B1 (en) |
ES (2) | ES2702148T3 (en) |
FI (1) | FIC20230028I1 (en) |
FR (1) | FR23C1030I1 (en) |
HK (1) | HK1215255A1 (en) |
HR (2) | HRP20220766T1 (en) |
HU (3) | HUE059409T2 (en) |
IL (1) | IL238610A0 (en) |
LT (3) | LT2922846T (en) |
MA (1) | MA38072A1 (en) |
MX (2) | MX2015005731A (en) |
MY (2) | MY194668A (en) |
NL (1) | NL301238I2 (en) |
NZ (1) | NZ708859A (en) |
PE (1) | PE20150944A1 (en) |
PH (1) | PH12015501004A1 (en) |
PL (2) | PL2922846T3 (en) |
PT (2) | PT2922846T (en) |
RS (2) | RS58187B1 (en) |
SG (3) | SG10201706897TA (en) |
SI (2) | SI2922846T1 (en) |
TR (1) | TR201820824T4 (en) |
TW (1) | TWI605041B (en) |
UY (1) | UY35126A (en) |
WO (1) | WO2014074661A1 (en) |
ZA (1) | ZA201504052B (en) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS58187B1 (en) | 2012-11-08 | 2019-03-29 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
KR102205914B1 (en) | 2012-11-08 | 2021-01-20 | 브리스톨-마이어스 스큅 컴퍼니 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
US10273237B2 (en) | 2013-12-10 | 2019-04-30 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses |
WO2015123453A1 (en) * | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
CN112851578A (en) * | 2015-11-26 | 2021-05-28 | 诺华股份有限公司 | Diaminopyridine derivatives |
US10323036B2 (en) | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
US10294256B2 (en) | 2016-12-13 | 2019-05-21 | Bristol-Myers Squibb Company | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses |
JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES |
CA3055209A1 (en) | 2017-03-08 | 2018-09-13 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors, uses, and methods for production thereof |
RS61816B1 (en) * | 2017-03-30 | 2021-06-30 | Bristol Myers Squibb Co | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
SG11202004592TA (en) | 2017-11-21 | 2020-06-29 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
WO2019178079A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
JP7485609B2 (en) * | 2018-03-22 | 2024-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | Pyridine-Containing Heterocyclic Compounds Useful as Modulators of IL-12, IL-23 and/or IFNα Responses - Patent application |
US11613529B2 (en) | 2018-05-31 | 2023-03-28 | Bristol-Myers Squibb Company | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide |
TWI842978B (en) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
EP3866789A4 (en) | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2020086616A1 (en) | 2018-10-22 | 2020-04-30 | Fronthera U.S. Pharmaceuticals Llc | Tyk2 inhibitors and uses thereof |
AU2019373203A1 (en) * | 2018-10-30 | 2021-06-10 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
CN113271938A (en) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | TYK2 inhibitors and uses thereof |
JP2022518505A (en) | 2019-01-23 | 2022-03-15 | ニンバス ラクシュミ, インコーポレイテッド | TYK2 inhibitors and their use |
JP2022524279A (en) * | 2019-01-28 | 2022-05-02 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | Pyridazine derivative inhibitor, its production method and use |
CN111484480B (en) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | Polycyclic derivative inhibitor, preparation method and application thereof |
AU2020216914A1 (en) * | 2019-01-30 | 2021-09-16 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
KR20220002488A (en) | 2019-04-30 | 2022-01-06 | 셀진 코포레이션 | Combination therapy comprising apremilast and a TYK2 inhibitor |
KR20220020890A (en) * | 2019-06-12 | 2022-02-21 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-( methyl-D3) crystalline salt form of pyridazine-3-carboxamide |
KR20220034853A (en) * | 2019-07-16 | 2022-03-18 | 브리스톨-마이어스 스큅 컴퍼니 | Prodrugs in the modulation of interleukins |
JP2022542704A (en) * | 2019-08-01 | 2022-10-06 | インテグラル バイオサイエンシーズ プライベート リミテッド | Heterocyclic compounds and their use as kinase inhibitors |
CA3150108A1 (en) | 2019-09-13 | 2021-03-18 | Neelu Kaila | Hpk1 antagonists and uses thereof |
BR112022004216A2 (en) * | 2019-09-18 | 2022-05-31 | Bristol Myers Squibb Co | Extended-release dosage forms for tyk2 inhibitors |
US20230039086A1 (en) * | 2019-12-17 | 2023-02-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Bms-986165 crystal form, preparation method therefor and use thereof |
WO2021143430A1 (en) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | Bms-986165 hydrochloride crystal form, preparation method therefor and use thereof |
US20230049130A1 (en) * | 2020-01-19 | 2023-02-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Deucravacitinib crystal form, preparation method therefor and use thereof |
US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
MX2022011297A (en) * | 2020-03-11 | 2022-10-07 | Beijing Innocare Pharma Tech Co Ltd | Heterocyclic compounds for inhibiting tyk2 activities. |
WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
CN113563309A (en) * | 2020-04-28 | 2021-10-29 | 浙江海正药业股份有限公司 | Pyridine derivative and preparation method and application thereof |
EP4143180A1 (en) * | 2020-04-28 | 2023-03-08 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
CN113735836B (en) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | Pyridazine compound and application thereof |
CN113735837B (en) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | Pyridazine compound and use thereof |
CN113773262B (en) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | Pyridazines compounds |
TW202214603A (en) * | 2020-07-24 | 2022-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | Crystal form of pyridazine derivative free base, preparation method, and application thereof |
EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
WO2022021684A1 (en) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | Crystalline form csv of bms-986165 hydrochloride, preparation method therefor, and uses thereof |
CN116472044A (en) | 2020-09-18 | 2023-07-21 | 百时美施贵宝公司 | Dosage form comprising a swellable core of a Tyk2 inhibitor |
CN116615200A (en) * | 2020-10-20 | 2023-08-18 | 杭州领业医药科技有限公司 | Crystalline forms of pyridazine derivatives |
US20240059671A1 (en) * | 2020-11-12 | 2024-02-22 | Cullgen (Shanghai), Inc. | Tyrosine kinase 2 (tyk2) degradation compounds and methods of use |
WO2022105771A1 (en) * | 2020-11-17 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | Nitrogen-containing heterocyclic derivative, and preparation method therefor and medical application thereof |
CN116547276A (en) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | TYK2 inhibitor compounds containing an amide group and a heterocycloalkyl group |
KR20230137962A (en) | 2021-01-29 | 2023-10-05 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-( Crystal form of methyl-D3)pyridazine-3-carboxamide |
MX2023009060A (en) | 2021-02-02 | 2023-09-29 | Liminal Biosciences Ltd | Gpr84 antagonists and uses thereof. |
WO2022167445A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
TW202233600A (en) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | TYK2 inhibitor compound containing bicyclic ring |
BR112023016590A2 (en) | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | TYK2 INHIBITORS AND THEIR USES |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
EP4308556A1 (en) * | 2021-03-16 | 2024-01-24 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
WO2022212181A1 (en) | 2021-03-29 | 2022-10-06 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
US20240182429A1 (en) * | 2021-03-30 | 2024-06-06 | Zhejiang Wenda Pharma Technology Ltd. | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use |
CN115197196B (en) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | TYK2 inhibitor and application thereof |
JP2024517453A (en) | 2021-05-04 | 2024-04-22 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | Nitrogen-containing heterocyclic pyridine compounds |
WO2022241173A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
WO2022241172A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
US20240270723A1 (en) | 2021-05-14 | 2024-08-15 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
TW202311247A (en) * | 2021-05-14 | 2023-03-16 | 美商必治妥美雅史谷比公司 | Substituted heterocyclic compounds |
WO2022253335A1 (en) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | Sulfonyl-containing aryl compound and application thereof |
CN117500796A (en) * | 2021-06-22 | 2024-02-02 | 南京明德新药研发有限公司 | Sulfinimides and application thereof |
EP4371981A1 (en) * | 2021-07-15 | 2024-05-22 | Medshine Discovery Inc. | Sulfur/phosphorus-containing aryl compound and application thereof |
EP4387968A1 (en) | 2021-08-20 | 2024-06-26 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
TW202313035A (en) * | 2021-08-21 | 2023-04-01 | 美商傳達治療有限公司 | Jak2 inhibitors and methods of use thereof |
CA3232812A1 (en) | 2021-09-23 | 2023-03-30 | Ian MacQuarie CATLETT | Methods of treating hair-loss disorders with tyk2 inhibitors |
WO2023055901A2 (en) | 2021-09-30 | 2023-04-06 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
MX2024004993A (en) | 2021-10-25 | 2024-05-07 | Kymera Therapeutics Inc | Tyk2 degraders and uses thereof. |
CN118434421A (en) | 2021-10-28 | 2024-08-02 | 百时美施贵宝公司 | External preparation of deuterium-celecoxib |
WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
TW202339749A (en) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Tyk2 inhibitors and compositions and methods thereof |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
CN116693449A (en) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | Compounds useful as TYK2 inhibitors, preparation method and application thereof in medicine |
WO2023231997A1 (en) * | 2022-05-31 | 2023-12-07 | 上海华汇拓医药科技有限公司 | Pyridazine compound, and preparation method therefor and use thereof |
WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
TW202416950A (en) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
TW202416972A (en) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024102683A1 (en) | 2022-11-08 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
WO2024127363A1 (en) | 2022-12-16 | 2024-06-20 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
CN116284040B (en) * | 2023-01-05 | 2024-05-28 | 华润医药研究院(深圳)有限公司 | Nitrogen-containing heterocyclic compound and medical application thereof |
WO2024165000A1 (en) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | Pyridazine compound, and preparation method therefor and use thereof |
CN116162093B (en) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | TYK2 inhibitor compound and application thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4622047B2 (en) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | Novel heterocyclic carboxamide derivatives |
US6797706B1 (en) * | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
WO2004007682A2 (en) | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
MX2012010265A (en) | 2010-03-17 | 2012-10-01 | Hoffmann La Roche | Imidazopyridine and purine compounds, compositions and methods of use. |
EP2616072A1 (en) | 2010-09-15 | 2013-07-24 | F.Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
JP2013542966A (en) | 2010-11-19 | 2013-11-28 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrazolopyridines and their use as TYK2 inhibitors and their use |
JP5878178B2 (en) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivatives |
CA2860547A1 (en) * | 2012-01-10 | 2013-07-18 | Johannes Cornelius Hermann | Pyridazine amide compounds and their use as syk inhibitors |
US20130310387A1 (en) * | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
CN104955805B (en) | 2012-10-19 | 2018-11-09 | 霍夫曼-拉罗奇有限公司 | The inhibitor of SYK |
WO2014074660A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
KR102205914B1 (en) | 2012-11-08 | 2021-01-20 | 브리스톨-마이어스 스큅 컴퍼니 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
RS58187B1 (en) * | 2012-11-08 | 2019-03-29 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
RS61816B1 (en) * | 2017-03-30 | 2021-06-30 | Bristol Myers Squibb Co | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
-
2013
- 2013-11-07 RS RS20181428A patent/RS58187B1/en unknown
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/en unknown
- 2013-11-07 PT PT13811640T patent/PT2922846T/en unknown
- 2013-11-07 PL PL13811640T patent/PL2922846T3/en unknown
- 2013-11-07 RS RS20220589A patent/RS63328B1/en unknown
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/en active Active
- 2013-11-07 MA MA38072A patent/MA38072A1/en unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/en unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/en unknown
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/en unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/en active IP Right Grant
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 EA EA201590917A patent/EA028814B1/en not_active IP Right Cessation
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/en unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/en active Active
- 2013-11-07 UY UY0001035126A patent/UY35126A/en unknown
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 ES ES13811640T patent/ES2702148T3/en active Active
- 2013-11-07 PL PL18197550T patent/PL3495358T3/en unknown
- 2013-11-07 AR ARP130104091A patent/AR094452A1/en active IP Right Grant
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/en unknown
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/en active IP Right Grant
- 2013-11-07 TW TW102140572A patent/TWI605041B/en active
- 2013-11-07 ES ES18197550T patent/ES2914793T3/en active Active
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en active Application Filing
- 2013-11-07 SI SI201331219T patent/SI2922846T1/en unknown
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/en active
- 2013-11-07 SI SI201331986T patent/SI3495358T1/en unknown
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/en unknown
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/en active IP Right Grant
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/en active IP Right Grant
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/en unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/en unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-03-21 HK HK16103247.7A patent/HK1215255A1/en unknown
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/en active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-11-21 HR HRP20181937TT patent/HRP20181937T1/en unknown
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/en unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/en active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en active Pending
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/en unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/en unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/en unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I1/en active Active
- 2023-08-23 LT LTPA2023523C patent/LTPA2023523I1/lt unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300025I1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha | |
HRP20191368T1 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses | |
EP2922841B8 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
PL2988756T3 (en) | Contrast medium formulation and related preparation method | |
GB201301626D0 (en) | Composition comprising 15-OHEPA and methods of using the same | |
EP2995308A4 (en) | Antihypoxic pharmaceutical composition and application thereof | |
EP3074028A4 (en) | Activity enhancing curcumin compositions and methods of use | |
EP2807256A4 (en) | Myonectin (ctrp15), compositions comprising same, and methods of use | |
EP2900916A4 (en) | Triggerable lost circulation material and method of use | |
HK1210264A1 (en) | Method of evaluating cellulite and method of evaluating cellulite- effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator -3 / | |
EP2900783A4 (en) | Dehydrated gel compositions and methods of using the same | |
ZA201502205B (en) | Ectoparasitic treatment method and composition | |
GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
AU2013902122A0 (en) | Ectoparasitic Treatment Method and Composition | |
GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
GB201301928D0 (en) | Composition and method of use thereof |